デジタルセラピューティクス(DTx)市場 : 2028年までの世界予測

出版:MarketsandMarkets(マーケッツアンドマーケッツ) 出版年月:2024年1月

Digital Therapeutics (DTX) Market – Global Forecast to 2028

デジタルセラピューティクス(DTx)市場 : 提供内容 (プラットフォーム、仮想現実/ゲーム)、収益モデル (サブスクリプション、バリューベース)、用途 (治療 (糖尿病、肥満、CNS、呼吸器、CVD)、服薬アドヒアランス、リハビリ/患者ケア) – 2028年までの世界予測
Digital Therapeutics (DTx) Market by Offerings (Platform, Virtual Reality/Games), Revenue Model (Subscription, Value Based), Application (Therapy (Diabetes, Obesity, CNS, Respiratory, CVD), Drug Adherence, Rehab/Patient care) – Global Forecast to 2028

ページ数297
図表数327
種別英文調査報告書
価格

お問合せ・ご注文  価格・納期について

Report Overview

The digital therapeutics market is projected to reach USD 21.9 billion by 2028 from USD 6.1 billion in 2023, at a CAGR of 29.1% during the forecast period.

デジタルセラピューティクス(DTx)市場は、予測期間中のCAGR 29.1%で、2023年の61億米ドルから2028年までに219億米ドルに達すると予測されています。

The rapid adoption of digital therapeutics is driven by factors such as the increasing number of patients grappling with chronic diseases and escalating investments in this sector. Nonetheless, impediments to market growth include a lack of awareness and access to digital therapeutics programs in developing nations, resistance from traditional healthcare providers, and the existence of uneven payment models.

デジタルセラピューティクス(DTx)市場 : 2028年までの世界予測


“The subscription-based revenue model segment represents the largest and fastest-growing category in the market over the forecast period.”
The revenue model segment the digital therapeutics market is categorized into subscription, one-time purchase/licensing, and outcome/value based. In 2022, the subscription segment held the largest market share. Digital therapeutics often aim for long-term health outcomes, requiring users to commit to the program over an extended period. Subscription models encourage user commitment by offering incentives and continuous access to the platform’s features.

“Diabetes segment is expected to grow at the highest rate during the forecast period.”
Concerning the type of treatment/care-related application, the digital therapeutics market is categorized into diabetes, CNS disorders, chronic respiratory diseases, musculoskeletal disorders, cardiovascular diseases, smoking cessation, medication adherence, gastrointestinal disorders, substance use disorders & addiction management, rehabilitation & patient care, and other treatment/care-related applications.
Within the category of treatment/care-related applications, the diabetes segment is poised to register the highest growth rate during the forecast period. The market for digital therapeutics in diabetes accounted for the largest share in 2022. The driving factors include the increasing prevalence of diabetes, the significant healthcare costs associated with the condition, and rising government initiatives focused on alleviating the burden through cost-effective solutions.

デジタルセラピューティクス(DTx)市場 : 2028年までの世界予測 ecosystem


“The B2B segment is expected to grow with the highest CAGR during the forecast period.”
With respect to the sales channel, the digital therapeutics market is segmented into business-to-customer (B2C) and business-to-business (B2B). The B2B segment is anticipated to exhibit the highest CAGR during the forecast period, attributed to the growing partnerships of pharmaceutical companies with digital health companies to integrate digital therapeutics with their drug products. Pharmaceutical companies are actively engaging in strategic partnerships and acquisitions with digital therapeutics providers. These collaborations allow pharmaceutical companies to integrate digital therapeutics into their broader healthcare solutions, offering a holistic approach to patient care. Additionally, payers, including insurance companies and healthcare providers, are increasingly embracing value-based care models. Digital therapeutics align with these models by emphasizing outcomes, prevention, and cost-effectiveness. Payers see the potential of DTx in reducing healthcare costs through preventive interventions, ultimately driving adoption.

“North America to be the largest and the fastest-growing regional market.”
North America, comprising of the US and Canada, held the lion’s share for digital therapeutics market in 2022. Factors such as the government schemes to fund technological advancements progresses combined with the favorable reimbursement structure for digital therapeutics are projected to the drive market growth in this region. Additionally, payers and healthcare providers in North America have been early adopters of digital therapeutics. The region has witnessed a proactive approach from insurance companies, healthcare providers, and other stakeholders in recognizing the clinical and cost-effectiveness of DTx. This early buy-in has driven widespread adoption across different healthcare settings.

デジタルセラピューティクス(DTx)市場 : 2028年までの世界予測 region

The primary interviews conducted for this report can be categorized as follows:
• By Company Type: Tier 1 (50%), Tier 2 (30%), and Tier 3 (20%)
• By Designation: C-level (75%), D-level (15%), and Others (10%)
• By Region: North America (70%), Europe (20%), APAC (7%), and the RoW (3%)

Key Players in the Digital Therapeutics Market
The prominent players in this market are Noom, Inc (US), Teladoc Health, Inc. (US), Omada Health, Inc. (US), WellDoc, Inc (US), Biofourmis (US), Better Therapeutics, Inc. (US), Amalgm Rx (US), CogniFit Inc (US), Headspace Health (US), Propeller Health (US), Virta Health Corp (US), 2Morrow, Inc. (US), Realizedcare (US), Canary Health (US), Twill Inc. (US), Click Therapeutics, Inc. (US), Akili, Inc. (US), Cognoa, Inc (US), Wellthy Therapeutics Pvt. Ltd. (India), Kaia Health (Germany), Ayogo (Canada), Mindable Health GmbH (Germany), Hinge Health, Inc. (US), and Freespira (US).


Research Coverage:
This report includes qualitative and quantitative analysis of the digital therapeutics market. The key objectives of the report are to estimate the size and future growth potential of the market across different segments, which includes sales channel, revenue model, application, offering and region. The report also comprises of extensive competitive analysis of the prominent market players, along with their financial information, recent developments, company profiles, recent developments, and prevalent market strategies.

Key Benefits of Buying the Report:
The report aims to assist market leaders and new entrants by offering close approximations of revenue figures for both the overall digital therapeutics market and its subsegments. Stakeholders can leverage this report to comprehend the competitive landscape, acquire insights for strategic business positioning, and formulate effective go-to-market strategies. Additionally, it provides stakeholders with the means to assess the market dynamics and furnishes information on crucial market opportunities, restraints, drivers, and challenges.

Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.


This report provides insights on:
n Analysis of key drivers (increasing incidence of preventable chronic disease, rising focus on preventative healthcare, need to control healthcare costs, significant increase in venture capital investments), opportunities (growth prospects in emerging markets, large undiagnosed and untreated patient population, unexpected therapeutic applications) are influencing the growth of the digital therapeutics market.
n Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the digital therapeutics market.
n Market Development: Comprehensive information detailing lucrative market – the report analyses the digital therapeutics market across various regions as well as countries.
n Market Diversification: Exhaustive information about new software and programs, untapped geographies, recent developments, and investments in the digital therapeutics market.
n Competitive Assessment: The report provides detailed insights on key players as well as key SME/upcoming players in the market. In-depth assessment of growth strategies, market shares, product and service offerings of players and key trends in the market is provided in the report. The report will enable stakeholders to understand the pulse of the digital therapeutics market and provide them with information such as drivers, challenges, restraints and opportunities.

Table of Contents

1            INTRODUCTION            40

1.1         STUDY OBJECTIVES      40

1.2         MARKET DEFINITION   40

1.3         INCLUSIONS AND EXCLUSIONS 40

1.4         MARKET SCOPE             41

1.4.1      MARKETS COVERED     41

1.4.2      YEARS CONSIDERED     42

1.4.3      CURRENCY CONSIDERED          42

1.5         STAKEHOLDERS            42

1.6         RESEARCH LIMITATIONS           43

1.7         SUMMARY OF CHANGES            43

1.8         RECESSION IMPACT      44

2            RESEARCH METHODOLOGY     45

2.1         RESEARCH DATA           45

FIGURE 1           RESEARCH DESIGN       45

2.1.1      SECONDARY DATA       46

2.1.1.1   Key data from secondary sources     47

2.1.2      PRIMARY DATA 47

FIGURE 2           PRIMARY SOURCES       47

2.1.2.1   Key data from primary sources         48

2.1.2.2   Key industry insights          49

FIGURE 3           BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION 50

FIGURE 4           BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY TYPE OF BUYER AND REGION   50

2.2         MARKET SIZE ESTIMATION       51

2.2.1      BOTTOM-UP APPROACH           51

2.2.1.1   Approach 1: Revenue mapping-based estimation         51

FIGURE 5           DIGITAL THERAPEUTICS: REVENUE MAPPING-BASED ESTIMATION    52

2.2.1.2   Approach 2: Buyer adoption-based estimation             52

FIGURE 6           DIGITAL THERAPEUTICS ESTIMATION: BUYER ADOPTION-BASED ESTIMATION     52

2.2.2      TOP-DOWN APPROACH: PENETRATION RATE-BASED MARKET SIZE ESTIMATION    53

FIGURE 7           PENETRATION RATE-BASED MARKET ESTIMATION      53

2.2.3      GROWTH FORECAST    53

TABLE 1             IMPACT ANALYSIS         54

FIGURE 8           CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2023–2028) 55

FIGURE 9           CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS   56

2.3         MARKET BREAKDOWN AND DATA TRIANGULATION    56

FIGURE 10         DATA TRIANGULATION METHODOLOGY         57

2.4         ASSUMPTIONS 57

2.5         RISK ASSESSMENT         58

3            EXECUTIVE SUMMARY 59

FIGURE 11         DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2023 VS. 2028 (USD MILLION) 59

FIGURE 12         DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2023 VS. 2028 (USD MILLION)             60

FIGURE 13         DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION)     60

FIGURE 14         DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2023 VS. 2028 (USD MILLION)          61

FIGURE 15         DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2023 VS. 2028 (USD MILLION)             62

FIGURE 16         GEOGRAPHICAL SNAPSHOT OF DIGITAL THERAPEUTICS MARKET            63

4            PREMIUM INSIGHTS      64

4.1         DIGITAL THERAPEUTICS MARKET OVERVIEW  64

FIGURE 17         INCREASING INCIDENCE OF CHRONIC DISEASES AND RISING NEED TO CURB HEALTHCARE COSTS TO DRIVE MARKET          64

4.2         DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2023 VS. 2O28              65

FIGURE 18         B2B SALES CHANNEL SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD     65

4.3         DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES           66

FIGURE 19         US TO GROW AT HIGHEST CAGR DURING FORECAST PERIOD              66

5            MARKET OVERVIEW     67

5.1         INTRODUCTION            67

5.2         MARKET DYNAMICS     67

FIGURE 20         DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    67

5.2.1      DRIVERS            68

5.2.1.1   Increasing incidence of chronic diseases         68

5.2.1.2   Growing focus on preventive healthcare        69

5.2.1.3   Rising need to curb healthcare cost  69

5.2.1.4   Surge in venture capital investments 70

5.2.1.5   Benefits of digital therapeutics         71

5.2.1.5.1 Ability to induce behavioral change 71

5.2.1.5.2 Improved drug adherence  71

5.2.1.5.3 Patient convenience and user-friendly           72

5.2.2      RESTRAINTS     72

5.2.2.1   Data privacy concerns        72

5.2.3      OPPORTUNITIES           72

5.2.3.1   High growth potential of emerging markets   72

5.2.3.2   Large undiagnosed and untreated population 73

5.2.4      CHALLENGES   73

5.2.4.1   Unstable pricing models    73

5.2.4.2   Reluctance among patients for DTx adoption 74

5.2.4.3   Limited awareness in emerging economies     74

5.2.4.4   Resistance from traditional healthcare providers          74

5.3         INDUSTRY TRENDS       75

5.3.1      VIRTUAL REALITY         75

5.3.2      RISING DEMAND FOR DIGITAL SOLUTIONS IN CBT       75

5.4         TECHNOLOGY ANALYSIS           76

TABLE 2             TECHNOLOGY ENABLERS, BENEFITS, AND EXAMPLES  76

5.4.1      MACHINE LEARNING    76

5.4.2      ARTIFICIAL INTELLIGENCE       77

5.4.3      INTERNET OF THINGS  77

5.4.4      BLOCKCHAIN TECHNOLOGY   77

5.4.5      CLOUD COMPUTING    78

5.4.6      DATA ANALYTICS         78

5.4.7      EXTENDED REALITY     78

5.5         VALUE CHAIN ANALYSIS            79

FIGURE 21         DIGITAL THERAPEUTICS MARKET: VALUE CHAIN ANALYSIS              79

5.5.1      RESEARCH & PRODUCT DEVELOPMENT            79

5.5.2      MATERIAL COMPONENTS         79

5.5.3      MANUFACTURERS & DEVELOPERS        80

5.5.4      DISTRIBUTION & SALES             80

5.5.5      END-USER INDUSTRIES 80

5.5.6      POST-SALE SERVICES   80

5.6         ECOSYSTEM ANALYSIS 81

FIGURE 22         ECOSYSTEM MARKET/MAP       81

5.7         PIPELINE PRODUCTS   84

5.8         CASE STUDY ANALYSIS 84

5.8.1      CASE STUDY 1: WELLTHY THERAPEUTICS (INDIA)        84

5.8.2      CASE STUDY 2: HAPPIFY HEALTH (US)  85

5.8.3      CASE STUDY 3: OMADA HEALTH (US)   85

5.9         PORTER’S FIVE FORCES ANALYSIS         85

5.9.1      THREAT OF NEW ENTRANTS    86

5.9.2      BARGAINING POWER OF SUPPLIERS     86

5.9.3      BARGAINING POWER OF BUYERS           86

5.9.4      THREAT OF SUBSTITUTES         87

5.9.5      INTENSITY OF COMPETITIVE RIVALRY 87

5.10       REGULATORY LANDSCAPE       87

5.10.1    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          88

TABLE 3             NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         88

TABLE 4             EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         90

TABLE 5             ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         92

TABLE 6             REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         94

TABLE 7             DIGITAL THERAPEUTICS MARKET: REGULATORY DATA NEEDED FOR CLASS II DEVICES 95

5.11       PRICING ANALYSIS        96

5.11.1    COSTS INVOLVED IN DIGITAL THERAPEUTICS 96

5.11.2    INDICATIVE PRICING ANALYSIS, BY KEY PLAYER & COUNTRY   96

TABLE 8             AVERAGE SELLING PRICE OF DIGITAL THERAPEUTIC PRODUCTS, BY COUNTRY         96

5.11.3    INDICATIVE PRICING ANALYSIS OF DIGITAL THERAPEUTICS, BY REGION             97

FIGURE 23         INDICATIVE PRICING ANALYSIS OF TELEHEALTH & TELEMEDICINE DEVICES, BY REGION   97

5.12       REIMBURSEMENT SCENARIO    98

TABLE 9             DIGITAL THERAPEUTICS MARKET: GLOBAL COVERAGE DETERMINATION STANDARDS 99

5.13       PATENT ANALYSIS        100

5.13.1    PATENT PUBLICATION TRENDS            100

FIGURE 24         LIST OF MAJOR PATIENTS FOR DIGITAL THERAPEUTICS              100

5.13.2    INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS        100

FIGURE 25         TOP APPLICANT COUNTRIES FOR DIGITAL THERAPEUTICS PATENTS (JANUARY 2016–NOVEMBER 2023)      101

5.13.3    LIST OF MAJOR PATENTS          101

TABLE 10           KEY PATENTS IN DIGITAL THERAPEUTICS MARKET     101

5.14       KEY CONFERENCES AND EVENTS          102

TABLE 11           DIGITAL THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS (2023−2024)         102

5.15       KEY STAKEHOLDERS AND BUYING CRITERIA    103

5.15.1    KEY STAKEHOLDERS IN BUYING PROCESS         103

FIGURE 26         INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL            103

TABLE 12           INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL, BY RANKING 103

5.15.2    BUYING CRITERIA         104

FIGURE 27         KEY BUYING CRITERIA FOR SALES CHANNEL    104

TABLE 13           KEY BUYING CRITERIA FOR SALES CHANNEL, BY RANKING              104

5.16       REVENUE SHIFT AND NEW REVENUE POCKETS FOR DIGITAL THERAPEUTICS MARKET           104

FIGURE 28         TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES              105

5.17       INVESTMENT LANDSCAPE        105

FIGURE 29         INVESTOR DEALS & FUNDING INITIATIVES FOR DIGITAL THERAPEUTICS (2022)  105

FIGURE 30         TOP FUNDING CATEGORIES FOR DIGITAL HEALTH IN 2021              106

FIGURE 31         MOST VALUED TELEHEALTH & TELEMEDICINE FIRMS IN 2022 (USD BILLION) 106

6            DIGITAL THERAPEUTICS MARKET, BY OFFERING          107

6.1         INTRODUCTION            108

TABLE 14           DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION) 108

6.2         SOFTWARE/PLATFORMS           108

6.2.1      ABILITY TO PROVIDE SCALABLE SOLUTIONS FOR DEPLOYMENT TO PROPEL MARKET          108

TABLE 15           DIGITAL THERAPEUTICS MARKET FOR SOFTWARE/PLATFORMS, BY REGION, 2021–2028 (USD MILLION)            109

6.3         PROGRAMS       109

6.3.1      INTRODUCTION OF EVIDENCE-BASED THERAPEUTIC PROGRAMS TO SUPPORT MARKET GROWTH    109

TABLE 16           DIGITAL THERAPEUTICS MARKET FOR PROGRAMS, BY REGION, 2021–2028 (USD MILLION)       110

6.4         VIRTUAL REALITY/GAMES        110

6.4.1      RISING DEMAND FOR VR SOLUTIONS TO DRIVE MARKET          110

TABLE 17           DIGITAL THERAPEUTICS MARKET FOR VIRTUAL REALITY/GAMES, BY REGION, 2021–2028 (USD MILLION)            111

7            DIGITAL THERAPEUTICS MARKET, BY APPLICATION    112

7.1         INTRODUCTION            113

TABLE 18           DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     113

7.2         TREATMENT/CARE-RELATED APPLICATIONS  113

TABLE 19           DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)  114

TABLE 20           DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)           114

7.2.1      DIABETES         115

7.2.1.1   Rising prevalence of diabetes to drive market 115

TABLE 21           DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2021–2028 (USD MILLION)          115

7.2.2      CENTRAL NERVOUS SYSTEM (CNS) DISORDERS             115

TABLE 22           DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)             116

TABLE 23           DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY REGION, 2021–2028 (USD MILLION)       116

7.2.2.1   Mental health disorders     116

7.2.2.1.1 Benefits of digital therapeutics in managing mental health disorders to drive R&D              116

TABLE 24           DIGITAL THERAPEUTICS MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2021–2028 (USD MILLION)       117

7.2.2.2   Other CNS disorders         117

TABLE 25           DIGITAL THERAPEUTICS MARKET FOR OTHER CNS DISORDERS, BY REGION, 2021–2028 (USD MILLION)       117

7.2.3      SMOKING CESSATION  118

7.2.3.1   Rising development of mobile applications for nicotine addiction treatment to drive market        118

TABLE 26           DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2021–2028 (USD MILLION)  118

7.2.4      CHRONIC RESPIRATORY DISEASES        118

7.2.4.1   Growing prevalence of COPD and asthma to drive market        118

TABLE 27           DIGITAL THERAPEUTICS MARKET FOR CHRONIC RESPIRATORY DISEASES, BY REGION, 2021–2028 (USD MILLION)             119

7.2.5      MUSCULOSKELETAL DISORDERS          119

7.2.5.1   Shortage of physiotherapists to boost demand              119

TABLE 28           DIGITAL THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)       119

7.2.6      CARDIOVASCULAR DISEASES   120

7.2.6.1   High incidence of CVD to propel market       120

TABLE 29           DIGITAL THERAPEUTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2021–2028 (USD MILLION)           120

7.2.7      MEDICATION ADHERENCE       120

7.2.7.1   Rising number of non-adherence cases to propel market            120

TABLE 30           DIGITAL THERAPEUTICS MARKET FOR MEDICATION ADHERENCE, BY REGION, 2021–2028 (USD MILLION)     121

7.2.8      GASTROINTESTINAL DISORDERS          121

7.2.8.1   Rising incidence of IBS and GERD to support market growth    121

TABLE 31           DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)       121

7.2.9      REHABILITATION & PATIENT CARE       122

7.2.9.1   Increasing focus on development of patient care platforms to drive market              122

TABLE 32           DIGITAL THERAPEUTICS MARKET FOR REHABILITATION & PATIENT CARE, BY REGION, 2021–2028 (USD MILLION) 122

7.2.10    SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT      122

7.2.10.1 Growing focus on behavioral interventions to propel market      122

TABLE 33           DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2021–2028 (USD MILLION)          123

7.2.11    OTHER TREATMENT/CARE-RELATED APPLICATIONS  123

TABLE 34           DIGITAL THERAPEUTICS MARKET FOR OTHER TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2021–2028 (USD MILLION)          123

7.3         PREVENTIVE APPLICATIONS    124

TABLE 35           DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      124

TABLE 36           DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 125

7.3.1      PREDIABETES  125

7.3.1.1   Focus on reducing type 2 diabetes to support market growth     125

TABLE 37           DIGITAL THERAPEUTICS MARKET FOR PREDIABETES, BY REGION, 2021–2028 (USD MILLION)       125

7.3.2      OBESITY            126

7.3.2.1   Availability of cost-effective solutions for obesity management to propel market              126

TABLE 38           DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2021–2028 (USD MILLION)          126

7.3.3      NUTRITION       126

7.3.3.1   Sedentary lifestyles and unhealthy diets to boost demand           126

TABLE 39           DIGITAL THERAPEUTICS MARKET FOR NUTRITION, BY REGION, 2021–2028 (USD MILLION)       127

7.3.4      LIFESTYLE MANAGEMENT        127

7.3.4.1   Aim to promote holistic lifestyles to drive market         127

TABLE 40           DIGITAL THERAPEUTICS MARKET FOR LIFESTYLE MANAGEMENT, BY REGION, 2021–2028 (USD MILLION) 127

7.3.5      OTHER PREVENTIVE APPLICATIONS    128

TABLE 41           DIGITAL THERAPEUTICS MARKET FOR OTHER PREVENTIVE APPLICATIONS, BY REGION, 2021–2028 (USD MILLION) 128

8            DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL           129

8.1         INTRODUCTION            130

TABLE 42           DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)     130

8.2         SUBSCRIPTION-BASED MODEL 130

8.2.1      FLEXIBILITY IN PAYMENT OPTIONS TO DRIVE MARKET            130

TABLE 43           DIGITAL THERAPEUTICS MARKET FOR SUBSCRIPTION-BASED MODEL, BY REGION, 2021–2028 (USD MILLION) 131

8.3         ONE-TIME PURCHASE/ANNUAL LICENSING MODEL     131

8.3.1      BENEFITS OF LIMITED RECURRING PAYMENTS TO BOOST DEMAND              131

TABLE 44           DIGITAL THERAPEUTICS MARKET FOR ONE-TIME PURCHASE/ANNUAL LICENSING MODEL, BY REGION, 2021–2028 (USD MILLION)          132

8.4         OUTCOME /VALUE-BASED MODEL       132

8.4.1      RESULT-DRIVEN APPROACH THAT ENHANCES END-USER ENGAGEMENT TO PROPEL MARKET     132

TABLE 45           DIGITAL THERAPEUTICS MARKET FOR OUTCOME/VALUE-BASED MODEL, BY REGION, 2021–2028 (USD MILLION) 133

9            DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL             134

9.1         INTRODUCTION            135

TABLE 46           DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)     135

9.2         B2B SALES CHANNEL    135

TABLE 47           DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)    135

TABLE 48           DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY REGION, 2021–2028 (USD MILLION)  136

9.2.1      PAYERS 136

9.2.1.1   Significant cost savings to boost demand        136

TABLE 49           DIGITAL THERAPEUTICS MARKET FOR PAYERS, BY REGION, 2021–2028 (USD MILLION)          137

9.2.2      EMPLOYERS     137

9.2.2.1   Rising importance of employee health management to drive market         137

TABLE 50           DIGITAL THERAPEUTICS MARKET FOR EMPLOYERS, BY REGION, 2021–2028 (USD MILLION)       138

9.2.3      PHARMACEUTICAL COMPANIES            138

9.2.3.1   Cross-industry collaborations between start-ups and pharma companies to propel market   138

TABLE 51           DIGITAL THERAPEUTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION)      139

9.2.4      PROVIDERS       139

9.2.4.1   Advanced patient management and cost-reduction benefits to support market growth   139

TABLE 52           DIGITAL THERAPEUTICS MARKET FOR PROVIDERS, BY REGION, 2021–2028 (USD MILLION)       140

9.2.5      OTHER BUYERS              140

TABLE 53           DIGITAL THERAPEUTICS MARKET FOR OTHER BUYERS, BY REGION, 2021–2028 (USD MILLION)       140

9.3         B2C SALES CHANNEL    141

TABLE 54           DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)    141

TABLE 55           DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY REGION, 2021–2028 (USD MILLION)  141

9.3.1      CAREGIVERS     142

9.3.1.1   Ability to manage chronic conditions effectively to boost demand            142

TABLE 56           DIGITAL THERAPEUTICS MARKET FOR CAREGIVERS, BY REGION, 2021–2028 (USD MILLION)       142

9.3.2      PATIENTS         142

9.3.2.1   Growing awareness of preventive health to support market        142

TABLE 57           DIGITAL THERAPEUTICS MARKET FOR PATIENTS, BY REGION, 2021–2028 (USD MILLION)          143

10          DIGITAL THERAPEUTICS MARKET, BY REGION 144

10.1       INTRODUCTION            145

TABLE 58           DIGITAL THERAPEUTICS MARKET, BY REGION, 2021–2028 (USD MILLION) 145

10.2       NORTH AMERICA          145

FIGURE 32         NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT        146

TABLE 59           NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    147

TABLE 60           NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)   147

TABLE 61           NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)    147

TABLE 62           NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           148

TABLE 63           NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          148

TABLE 64           NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          149

TABLE 65           NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            149

TABLE 66           NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)      149

TABLE 67           NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 150

TABLE 68           NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 150

10.2.1    NORTH AMERICA: RECESSION IMPACT 150

10.2.2    US         151

10.2.2.1 Rising technological advancements to boost demand    151

TABLE 69           US: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)     152

TABLE 70           US: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)          152

TABLE 71           US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     152

TABLE 72           US: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          153

TABLE 73           US: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      153

TABLE 74           US: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)       154

TABLE 75           US: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)          154

TABLE 76           US: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            154

TABLE 77           US: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            155

10.2.3    CANADA            155

10.2.3.1 Favorable government initiatives for advanced healthcare solutions to support market growth     155

TABLE 78           CANADA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)          156

TABLE 79           CANADA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        156

TABLE 80          CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          157

TABLE 81           CANADA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          157

TABLE 82           CANADA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      158

TABLE 83           CANADA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            158

TABLE 84           CANADA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)    158

TABLE 85           CANADA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            159

TABLE 86           CANADA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            159

10.3       EUROPE             159

TABLE 87           EUROPE: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)          160

TABLE 88           EUROPE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)          160

TABLE 89           EUROPE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        161

TABLE 90           EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          161

TABLE 91           EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          162

TABLE 92           EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      162

TABLE 93           EUROPE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            163

TABLE 94           EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)    163

TABLE 95           EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            163

TABLE 96           EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            164

10.3.1    EUROPE: RECESSION IMPACT   164

10.3.2    GERMANY         164

10.3.2.1 Rising investments in digital health applications to drive market 164

TABLE 97           GERMANY: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)          165

TABLE 98           GERMANY: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        165

TABLE 99           GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           165

TABLE 100         GERMANY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          166

TABLE 101         GERMANY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          166

TABLE 102         GERMANY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            167

TABLE 103         GERMANY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)    167

TABLE 104         GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            167

TABLE 105         GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            168

10.3.3    UK         168

10.3.3.1 High adoption of HCIT solutions to propel market      168

TABLE 106         UK: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)     169

TABLE 107         UK: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)          169

TABLE 108         UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          169

TABLE 109         UK: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          170

TABLE 110         UK: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      170

TABLE 111         UK: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)       171

TABLE 112         UK: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)          171

TABLE 113         UK: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            171

TABLE 114         UK: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            172

10.3.4    FRANCE             172

10.3.4.1 Favorable health insurance system to boost demand     172

TABLE 115         FRANCE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)          172

TABLE 116         FRANCE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        173

TABLE 117         FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          173

TABLE 118         FRANCE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          174

TABLE 119         FRANCE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      174

TABLE 120         FRANCE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            175

TABLE 121         FRANCE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)    175

TABLE 122         FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            175

TABLE 123         FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            176

10.3.5    SPAIN   176

10.3.5.1 Rising incidence of chronic diseases to support market growth   176

TABLE 124         SPAIN: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)     177

TABLE 125         SPAIN: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        177

TABLE 126         SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          177

TABLE 127         SPAIN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          178

TABLE 128         SPAIN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      178

TABLE 129         SPAIN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            179

TABLE 130        SPAIN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)          179

TABLE 131         SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            179

TABLE 132         SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            180

10.3.6    ITALY   180

10.3.6.1 Increasing focus on preventive care to support market growth    180

TABLE 133         ITALY: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)     180

TABLE 134         ITALY: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        181

TABLE 135         ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          181

TABLE 136         ITALY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          182

TABLE 137         ITALY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      182

TABLE 138         ITALY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            183

TABLE 139        ITALY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)          183

TABLE 140         ITALY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            183

TABLE 141         ITALY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            184

10.3.7    REST OF EUROPE           184

TABLE 142         REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)   185

TABLE 143         REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)    185

TABLE 144         REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           185

TABLE 145         REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          186

TABLE 146         REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          186

TABLE 147         REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            187

TABLE 148         REST OF EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)      187

TABLE 149         REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 187

TABLE 150         REST OF EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 188

10.4       ASIA PACIFIC    188

TABLE 151         ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2021–2028 (USD MILLION)    188

TABLE 152         ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)   189

TABLE 153         ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        189

TABLE 154         ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           189

TABLE 155         ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          190

TABLE 156         ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          190

TABLE 157         ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            191

TABLE 158         ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)    191

TABLE 159         ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 191

TABLE 160         ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 192

10.4.1    ASIA PACIFIC: RECESSION IMPACT        192

10.4.2    JAPAN  193

10.4.2.1 Rising incidence of diabetes to propel market 193

TABLE 161         JAPAN: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)     193

TABLE 162         JAPAN: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        193

TABLE 163         JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          194

TABLE 164         JAPAN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          194

TABLE 165         JAPAN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      195

TABLE 166         JAPAN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            195

TABLE 167        JAPAN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)          195

TABLE 168         JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            196

TABLE 169         JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            196

10.4.3    CHINA  196

10.4.3.1 Rising investments in application development to propel market              196

TABLE 170         CHINA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)          197

TABLE 171         CHINA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        197

TABLE 172         CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          197

TABLE 173         CHINA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          198

TABLE 174         CHINA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      198

TABLE 175         CHINA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            199

TABLE 176         CHINA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)    199

TABLE 177         CHINA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            199

TABLE 178         CHINA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            200

10.4.4    INDIA   200

10.4.4.1 Low patient adherence to prescribed treatments to support market growth              200

TABLE 179         INDIA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)     200

TABLE 180         INDIA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        201

TABLE 181         INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          201

TABLE 182         INDIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          202

TABLE 183         INDIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      202

TABLE 184         INDIA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            203

TABLE 185        INDIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)          203

TABLE 186         INDIA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            203

TABLE 187         INDIA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            204

10.4.5    REST OF ASIA PACIFIC  204

TABLE 188         REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)   204

TABLE 189         REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)    205

TABLE 190         REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           205

TABLE 191         REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          206

TABLE 192         REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          206

TABLE 193         REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)    207

TABLE 194         REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)      207

TABLE 195         REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)       207

TABLE 196         REST OF ASIA PACIFIC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)       208

10.5       LATIN AMERICA             208

TABLE 197         LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)   208

TABLE 198         LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)    209

TABLE 199         LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           209

TABLE 200         LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          210

TABLE 201         LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          210

TABLE 202         LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            211

TABLE 203         LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)    211

TABLE 204         LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 211

TABLE 205         LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 212

10.5.1    LATIN AMERICA: RECESSION IMPACT   212

10.5.2    BRAZIL 212

10.5.2.1 Growing acceptance of evidence-based software applications to boost demand              212

TABLE 206         BRAZIL: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)          213

TABLE 207         BRAZIL: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        213

TABLE 208         BRAZIL: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          213

TABLE 209         BRAZIL: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)     214

TABLE 210         BRAZIL: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      214

TABLE 211         BRAZIL: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            215

TABLE 212         BRAZIL: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)    215

TABLE 213         BRAZIL: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            215

TABLE 214         BRAZIL: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            216

10.5.3    MEXICO             216

10.5.3.1 Growth in target patient population to support market growth   216

TABLE 215         MEXICO: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)          216

TABLE 216         MEXICO: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)        217

TABLE 217         MEXICO: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)          217

TABLE 218         MEXICO: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          218

TABLE 219         MEXICO: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)      218

TABLE 220         MEXICO: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            219

TABLE 221         MEXICO: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)    219

TABLE 222         MEXICO: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            219

TABLE 223         MEXICO: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            220

10.5.4    REST OF LATIN AMERICA          220

TABLE 224         REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)            220

TABLE 225         REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)            221

TABLE 226         REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     221

TABLE 227         REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          222

TABLE 228         REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 222

TABLE 229         REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)         223

TABLE 230         REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 223

TABLE 231         REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            223

TABLE 232         REST OF LATIN AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            224

10.6       MIDDLE EAST & AFRICA             224

TABLE 233         MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)            224

TABLE 234         MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)            225

TABLE 235         MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)     225

TABLE 236         MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          226

TABLE 237         MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION) 226

TABLE 238         MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)         227

TABLE 239         MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION) 227

TABLE 240         MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            227

TABLE 241         MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)            228

10.6.1    MIDDLE EAST & AFRICA: RECESSION IMPACT   228

10.6.2    GCC COUNTRIES           228

10.6.2.1 Improvements in healthcare infrastructure to drive market        228

TABLE 242         GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)   229

TABLE 243         GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)    229

TABLE 244         GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)           229

TABLE 245         GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/ CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          230

TABLE 246         GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)          230

TABLE 247         GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)            231

TABLE 248         GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)    231

TABLE 249         GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 231

TABLE 250         GCC COUNTRIES: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION) 232

10.6.3    REST OF MIDDLE EAST & AFRICA           232

TABLE 251         REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY OFFERING, 2021–2028 (USD MILLION)        232

TABLE 252         REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY REVENUE MODEL, 2021–2028 (USD MILLION)         233

TABLE 253         REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2021–2028 (USD MILLION)  233

TABLE 254         REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)     234

TABLE 255         REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2021–2028 (USD MILLION)              234

TABLE 256         REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2021–2028 (USD MILLION)       235

TABLE 257         REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2021–2028 (USD MILLION)           235

TABLE 258         REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)              235

TABLE 259         REST OF MIDDLE EAST & AFRICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2021–2028 (USD MILLION)              236

11          COMPETITIVE LANDSCAPE       237

11.1       OVERVIEW        237

11.2       KEY PLAYER STRATEGIES          237

FIGURE 33         OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS              238

11.3       REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 238

11.3.1    REVENUE ANALYSIS OF KEY PLAYERS IN DIGITAL THERAPEUTICS MARKET, 2020–2022 (USD MILLION)      239

11.4       MARKET SHARE ANALYSIS         239

TABLE 260         DIGITAL THERAPEUTICS MARKET: INTENSITY OF COMPETITIVE RIVALRY             239

FIGURE 34         DIGITAL THERAPEUTICS MARKET: MARKET SHARE ANALYSIS              240

11.5       COMPANY EVALUATION MATRIX          241

11.5.1    STARS  241

11.5.2    EMERGING LEADERS    241

11.5.3    PERVASIVE PLAYERS     241

11.5.4    PARTICIPANTS 241

FIGURE 35         DIGITAL THERAPEUTICS MARKET: COMPANY EVALUATION MATRIX (2022) 242

11.5.5    COMPANY FOOTPRINT 242

TABLE 261         DIGITAL THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS        242

TABLE 262         DIGITAL THERAPEUTICS MARKET: OFFERING FOOTPRINT ANALYSIS, BY KEY PLAYER        244

TABLE 263         DIGITAL THERAPEUTICS MARKET: APPLICATION FOOTPRINT ANALYSIS, BY KEY PLAYER        245

TABLE 264         DIGITAL THERAPEUTICS MARKET: SALES CHANNEL FOOTPRINT ANALYSIS, BY KEY PLAYER 246

TABLE 265         DIGITAL THERAPEUTICS MARKET: REGIONAL FOOTPRINT ANALYSIS, BY KEY PLAYER        247

11.6       COMPANY EVALUATION MATRIX FOR STARTUPS/SMES             248

11.6.1    PROGRESSIVE COMPANIES       248

11.6.2    RESPONSIVE COMPANIES          248

11.6.3    DYNAMIC COMPANIES 248

11.6.4    STARTING BLOCKS       249

FIGURE 36         DIGITAL THERAPEUTICS MARKET: STARTUP/SME EVALUATION MATRIX (2022)    249

11.6.5    COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES         250

TABLE 266         DETAILED LIST OF KEY STARTUPS/SMES           250

TABLE 267         COMPETITIVE BENCHMARKING OF STARTUPS/SMES, BY REGION             251

11.7       COMPETITIVE SCENARIOS AND TRENDS           251

TABLE 268         DIGITAL THERAPEUTICS MARKET: PRODUCT LAUNCHES, ENHANCEMENTS, AND APPROVALS (JANUARY 2020–NOVEMBER 2023) 251

11.7.1    DEALS  254

TABLE 269         DIGITAL THERAPEUTICS MARKET: DEALS (JANUARY 2020–NOVEMBER 2023)          254

11.7.2    OTHER DEVELOPMENTS           258

TABLE 270         DIGITAL THERAPEUTICS MARKET: OTHER DEVELOPMENTS (JANUARY 2020–NOVEMBER 2023)          258

12          COMPANY PROFILES    260

12.1       KEY PLAYERS   260

(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*

12.1.1    NOOM, INC.      260

TABLE 271         NOOM, INC.: BUSINESS OVERVIEW        260

12.1.2    TELADOC HEALTH, INC.            263

TABLE 272         TELADOC HEALTH, INC.: BUSINESS OVERVIEW 263

FIGURE 37         TELADOC HEALTH, INC.: COMPANY SNAPSHOT (2022) 263

12.1.3    OMADA HEALTH, INC.  266

TABLE 273         OMADA HEALTH, INC.: BUSINESS OVERVIEW    266

12.1.4    WELLDOC, INC.              269

TABLE 274         WELLDOC, INC.: BUSINESS OVERVIEW  269

12.1.5    COGNIFIT, INC. 271

TABLE 275         COGNIFIT, INC.: BUSINESS OVERVIEW  271

12.1.6    HEADSPACE HEALTH   273

TABLE 276         HEADSPACE HEALTH: BUSINESS OVERVIEW     273

12.1.7    PROPELLER HEALTH    275

TABLE 277         PROPELLER HEALTH: BUSINESS OVERVIEW      275

12.1.8    2MORROW, INC.             277

TABLE 278         2MORROW, INC.: BUSINESS OVERVIEW 277

12.1.9    CANARY HEALTH          279

TABLE 279         CANARY HEALTH: BUSINESS OVERVIEW            279

12.1.10  CLICK THERAPEUTICS, INC.      281

TABLE 280         CLICK THERAPEUTICS: BUSINESS OVERVIEW   281

12.1.11  AKILI, INC.         283

TABLE 281         AKILI, INC.: BUSINESS OVERVIEW          283

12.1.12  WELLTHY THERAPEUTICS PVT. LTD.    285

TABLE 282         WELLTHY THERAPEUTICS PVT. LTD.: BUSINESS OVERVIEW              285

12.1.13  COGNOA, INC.  287

TABLE 283         COGNOA, INC.: BUSINESS OVERVIEW    287

12.1.14  TWILL INC.        289

TABLE 284         TWILL INC.: BUSINESS OVERVIEW         289

12.1.15  KAIA HEALTH SOFTWARE GMBH           290

TABLE 285         KAIA HEALTH SOFTWARE GMBH: BUSINESS OVERVIEW              290

12.1.16  BETTER THERAPEUTICS, INC.   292

TABLE 286         BETTER THERAPEUTICS, INC.: BUSINESS OVERVIEW     292

12.1.17  REALIZEDCARE 294

TABLE 287         REALIZEDCARE: BUSINESS OVERVIEW  294

12.1.18  BIOFOURMIS    295

TABLE 288         BIOFOURMIS: BUSINESS OVERVIEW      295

12.1.19  AYOGO INCORPORATED           296

TABLE 289         AYOGO INCORPORATED: BUSINESS OVERVIEW             296

12.1.20  AMALGAM RX, INC.        298

TABLE 290         AMALGAM RX, INC.: BUSINESS OVERVIEW         298

12.2       OTHER PLAYERS           299

12.2.1    MINDABLE HEALTH GMBH       299

12.2.2    VIRTA HEALTH CORP.  299

12.2.3    HINGE HEALTH             300

12.2.4    OREXO AB         300

12.2.5    FREESPIRA, INC.             301

*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.

13          APPENDIX         302

13.1       DISCUSSION GUIDE      302

13.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             306

13.3       CUSTOMIZATION OPTIONS      308

13.4       RELATED REPORTS       308

13.5       AUTHOR DETAILS         309